Skip to content

A single-center study on the efficacy of first-line drugs for chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation graft-versus-host disease (cGVHD)

A single-center study on the efficacy of first-line drugs for chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation graft-versus-host disease (cGVHD)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500097322
Enrollment
Unknown
Registered
2025-02-17
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cGVHD

Interventions

Observation group:None

Sponsors

The Second Affiliated Hospital of Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 70 Years

Inclusion criteria

Inclusion criteria: (1) Allogeneic hematopoietic stem cell transplantation was performed to treat hematological diseases and follow-up conditions were available after transplantation, regardless of gender; (2) Self-reported active cGVHD symptoms; (3) cGVHD that was diagnosed as requiring systemic treatment by out-patient physicians and received first-line treatment during follow-up;

Exclusion criteria

Exclusion criteria: (1) There is serious organ dysfunction or insufficiency; (2) Clinically uncontrolled active infection; (3) having a serious infectious disease; (4) Lack of transplant data or follow-up data

Design outcomes

Primary

MeasureTime frame
Overall response rate;Complete response rate;

Secondary

MeasureTime frame
Organ response rate;Patient-reported outcome;Event-Free Survival;Overall Survival;Satefy;

Countries

China

Contacts

Public ContactXi Zhang

The Second Affiliated Hospital of Army Medical University

zhangxxi@sina.com+86 138 0831 0064

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026